About euroapi sa - EAPIF
EUROAPI SA engages in manufacturing and supply of active pharmaceutical ingredient solutions for healthcare companies. The company was founded on November 10, 2020, and is headquartered in Gentilly, France.
EAPIF At a Glance
EUROAPI SA
15 rue Traversière
Paris, Ile-de-France 75012
| Phone | 33-1-89-20-62-00 | Revenue | 986.39M | |
| Industry | Biotechnology | Net Income | -141,268,812.78 | |
| Sector | Health Technology | Employees | 3,428 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
EAPIF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.286 |
| Price to Book Ratio | 0.279 |
| Price to Cash Flow Ratio | 2.33 |
| Enterprise Value to EBITDA | 5.429 |
| Enterprise Value to Sales | 0.282 |
| Total Debt to Enterprise Value | 0.258 |
EAPIF Efficiency
| Revenue/Employee | 287,746.15 |
| Income Per Employee | -41,210.272 |
| Receivables Turnover | 4.878 |
| Total Asset Turnover | 0.594 |
EAPIF Liquidity
| Current Ratio | 2.528 |
| Quick Ratio | 0.932 |
| Cash Ratio | 0.222 |
EAPIF Profitability
| Gross Margin | 14.738 |
| Operating Margin | -1.217 |
| Pretax Margin | -15.309 |
| Net Margin | -14.322 |
| Return on Assets | -8.501 |
| Return on Equity | -13.828 |
| Return on Total Capital | -12.961 |
| Return on Invested Capital | -13.623 |
EAPIF Capital Structure
| Total Debt to Total Equity | 7.026 |
| Total Debt to Total Capital | 6.565 |
| Total Debt to Total Assets | 4.639 |
| Long-Term Debt to Equity | 1.342 |
| Long-Term Debt to Total Capital | 1.254 |